Halozyme Therapeutics Inc.

+4.21 (+8.92%)
4:25:47 PM EDT: $51.79 +0.37 (+0.72%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.95B
Current PE53.85
Forward PE 55.29
2yr Forward PE 30.25
See more stats
Estimates Current Quarter
Revenue$118.65 Million
Adjusted EPS$0.52
See more estimates
10-Day MA$49.64
50-Day MA$46.30
200-Day MA$33.45
See more pivots

Halozyme Therapeutics, Inc. Stock, NASDAQ:HALO

11388 Sorrento Valley Road, San Diego, California 92121
United States of America
Phone: +1.858.794.8889
Number of Employees: 132


Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.